For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $13.82 in the prior trading day, Immunome Inc (NASDAQ: IMNM) closed at $14.01, up 1.37%. In other words, the price has increased by $1.37 from its previous closing price. On the day, 1.83 million shares were traded. IMNM stock price reached its highest trading level at $14.78 during the session, while it also had its lowest trading level at $13.78.
Ratios:
Our goal is to gain a better understanding of IMNM by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.13 and its Current Ratio is at 12.13. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on September 22, 2025, initiated with a Buy rating and assigned the stock a target price of $26.
On September 05, 2025, Craig Hallum started tracking the stock assigning a Buy rating and target price of $26.
On April 02, 2025, Lake Street started tracking the stock assigning a Buy rating and target price of $23.Lake Street initiated its Buy rating on April 02, 2025, with a $23 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 03 ’25 when BIENAIME JEAN JACQUES bought 5,000 shares for $9.38 per share. The transaction valued at 46,900 led to the insider holds 36,415 shares of the business.
BIENAIME JEAN JACQUES bought 7,800 shares of IMNM for $60,684 on Mar 25 ’25. The Director now owns 31,415 shares after completing the transaction at $7.78 per share. On Mar 26 ’25, another insider, SIEGALL CLAY B, who serves as the President and CEO of the company, bought 137,100 shares for $7.29 each. As a result, the insider paid 999,459 and bolstered with 806,736 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMNM now has a Market Capitalization of 1219500544 and an Enterprise Value of 955606592. For the stock, the TTM Price-to-Sale (P/S) ratio is 96.86 while its Price-to-Book (P/B) ratio in mrq is 4.53. Its current Enterprise Value per Revenue stands at 75.908 whereas that against EBITDA is -5.072.
Stock Price History:
The Beta on a monthly basis for IMNM is 1.94, which has changed by 0.18028641 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, IMNM has reached a high of $15.12, while it has fallen to a 52-week low of $5.15. The 50-Day Moving Average of the stock is 34.73%, while the 200-Day Moving Average is calculated to be 48.68%.
Shares Statistics:
The stock has traded on average 1.17M shares per day over the past 3-months and 2030730 shares per day over the last 10 days, according to various share statistics. A total of 87.01M shares are outstanding, with a floating share count of 79.76M. Insiders hold about 8.37% of the company’s shares, while institutions hold 85.14% stake in the company. Shares short for IMNM as of 1757894400 were 14973353 with a Short Ratio of 12.75, compared to 1755216000 on 13763815. Therefore, it implies a Short% of Shares Outstanding of 14973353 and a Short% of Float of 17.969999.
Earnings Estimates
The dynamic stock of Immunome Inc (IMNM) is currently attracting attention from 9.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.45 and low estimates of -$0.73.
Analysts are recommending an EPS of between -$1.74 and -$2.4 for the fiscal current year, implying an average EPS of -$2.09. EPS for the following year is -$2.36, with 9.0 analysts recommending between -$1.63 and -$2.79.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for IMNM’s current fiscal year. The highest revenue estimate was $16M, while the lowest revenue estimate was $6.9M, resulting in an average revenue estimate of $8.54M. In the same quarter a year ago, actual revenue was $9.04M
